TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01631383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-THP (l-tetrahydropalmatine)
Description: Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
Study: NCT02593357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COPD patients
Description: measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
Study: NCT04154098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scapula orthosis assistance
Description: Participants are elevating their arm while their scapula is assisted by the scapula orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scapula orthosis assistance
Description: Participants are elevating their arm while their scapula is assisted by the scapula orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scapula orthosis assistance
Description: Participants are elevating their arm while their scapula is assisted by the scapula orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scapula orthosis assistance
Description: Participants are elevating their arm while their scapula is assisted by the scapula orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scapula orthosis assistance
Description: Participants are elevating their arm while their scapula is assisted by the scapula orthosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual scapula assistance
Description: Participants are elevating their arm while their scapula is assisted by a trained personnel
Study: NCT00184873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Counseling
Study: NCT04154098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual scapula assistance
Description: Participants are elevating their arm while their scapula is assisted by a trained personnel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual scapula assistance
Description: Participants are elevating their arm while their scapula is assisted by a trained personnel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual scapula assistance
Description: Participants are elevating their arm while their scapula is assisted by a trained personnel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual scapula assistance
Description: Participants are elevating their arm while their scapula is assisted by a trained personnel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual scapula assistance
Description: Participants are elevating their arm while their scapula is assisted by a trained personnel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No assistance
Description: Participants are elevating their arm without being assisted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No assistance
Description: Participants are elevating their arm without being assisted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No assistance
Description: Participants are elevating their arm without being assisted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No assistance
Description: Participants are elevating their arm without being assisted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No assistance
Description: Participants are elevating their arm without being assisted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No assistance
Description: Participants are elevating their arm without being assisted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Test
Description: Participants perform a functional test once without (NO) and once with (OA) the orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Test
Description: Participants perform a functional test once without (NO) and once with (OA) the orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Test
Description: Participants perform a functional test once without (NO) and once with (OA) the orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Test
Description: Participants perform a functional test once without (NO) and once with (OA) the orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Test
Description: Participants perform a functional test once without (NO) and once with (OA) the orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Test
Description: Participants perform a functional test once without (NO) and once with (OA) the orthosis
Study: NCT03075839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette Brand Switching
Description: Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
Study: NCT02213718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: desflurane (7%-8% end-tidal concentration)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol (TCI:3.5-4.0μg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil
Description: TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
Study: NCT03670017

Intervention type: DEVICE
Group type: OTHER
Intervention: OptiScanner® 5000 Glucose Monitoring System
Description: The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device \[i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.
Study: NCT00681161

Intervention type: OTHER
Group type: OTHER
Intervention: continuous positive airway pressure (CPAP)
Description: Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
Study: NCT02723721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picato gel
Description: apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
Study: NCT01292590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: 40 grams saturated fat
Study: NCT01816997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: placebo
Study: NCT02819323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS
Description: polyethylene glycol based bowel preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800
Description: BLI800 bowel preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800
Description: BLI800 bowel preparation
Study: NCT00476281

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urinary collect

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuous Glucose Monitoring System (CGMS)
Study: NCT04206358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrienX010 combination with JS001
Description: OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10\^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
Study: NCT02648074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial challenge with allergen
Description: Bronchial challenge is performed with D. pteronyssinus allergen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial challenge with allergen
Description: Bronchial challenge is performed with D. pteronyssinus allergen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-culture formation
Description: Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Co-culture formation
Description: Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
Study: NCT02474888

Intervention type: OTHER
Intervention: blood specimen
Description: blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
Study: NCT00579345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell culture derived seasonal trivalent influenza vaccine (cTIV)
Description: cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
Description: egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cTIV or eTIV_a
Description: 0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV_a administered.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cTIV+PV OR eTIV_a+PV
Description: 0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
Study: NCT03498391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Injectable Product
Description: Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
Study: NCT02109263

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saccharose versus breast-feeding
Description: saccharose versus breast-feeding
Study: NCT04501562

Intervention type: OTHER
Intervention: Examinations
Description: Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.

Intervention type: OTHER
Intervention: Cardiovascular Tests
Description: Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
Study: NCT02989389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3323795
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3323795
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3323795
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3323795
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01018979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-0054 (2.24 mg/kg)
Description: TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-0054 (3.14 mg/kg)
Description: TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Study: NCT03295851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate
Description: Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
Study: NCT04248361

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TEM-PCR URI Panel
Description: Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC/Empiric Diagnosis
Description: The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
Study: NCT02278354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 megabecquerel (MBq) (10 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 megabecquerel (MBq) (10 mCi)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain 75-105 minutes post injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain 75-105 minutes post injection
Study: NCT00790036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus Placebo
Description: Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
Study: NCT02802722

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 supplementation
Description: Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral blood and induced sputum sampling
Description: To attain samples for immunological testing

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood and induced sputum sampling
Description: To attain samples for immunological testing

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Chest computerised tomography (CT) scans
Description: For volumetric quantification of lung abnormalities

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chest computerised tomography (CT) scans
Description: For volumetric quantification of lung abnormalities

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptom questionnaire
Description: Symptom questionnaire for recent symptom history

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom questionnaire
Description: Symptom questionnaire for recent symptom history

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To be dispensed using an electronic dispenser to allow real time logging of adherence.
Study: NCT01054248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Description: Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemeter-lumefantrin
Description: Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
Study: NCT03297697

Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load

Intervention type: PROCEDURE
Intervention: Peripheral blood draw
Description: -Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse

Intervention type: PROCEDURE
Intervention: Lymphotrack TCR clonality assay
Description: -Assay with high sensitivity that can be performed with peripheral blood
Study: NCT04501562

Intervention type: OTHER
Intervention: Bio-specimen collection
Description: Bio-specimens collected will include fresh blood, urine and/or stool specimens.

Intervention type: OTHER
Intervention: Clinical/health outcome collection
Description: Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
Study: NCT00294125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavocoxid
Description: Daily flavocoxid for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo for 12 weeks
Study: NCT04425655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2 days 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: 100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
Study: NCT03912636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing
Description: Subjects will perform Diaphragmatic breathing after the test meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing
Description: Subjects will perform Diaphragmatic breathing after the test meal.
Study: NCT02687269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
Study: NCT03912636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing
Description: Subjects will perform Diaphragmatic breathing after the test meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep Slow Breathing
Description: Subjects will perform Deep Slow Breathing after the test meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep Slow Breathing
Description: Subjects will perform Deep Slow Breathing after the test meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep Slow Breathing
Description: Subjects will perform Deep Slow Breathing after the test meal.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal breathing
Description: Subjects will perform Normal Breathing (as a control) after the test meal as a control.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal breathing
Description: Subjects will perform Normal Breathing (as a control) after the test meal as a control.
Study: NCT04652310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFNA extended-short nail (235 mm)
Description: The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
Study: NCT02687269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive Placebo twice daily in the three days before surgery
Study: NCT01596491

Intervention type: PROCEDURE
Intervention: quantitative sensory testing (QST)
Description: with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified

Intervention type: PROCEDURE
Intervention: quantitative sensory testing (QST)
Description: with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
Study: NCT01815814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rolfing / Myofascial Structural Integration
Description: Rolfing is similar to deep massage. It is also known as myofascial structural integration.

Intervention type: OTHER
Group type: OTHER
Intervention: Rolfing / Myofascial Structural Integration
Description: Rolfing is similar to deep massage. It is also known as myofascial structural integration.